Myriad Genetics Launches Prolaris + AI Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2026
0mins
Myriad Genetics announced the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.1-4 This combination helps identify if a patient is safe for active surveillance, or AS, and how refinement of AS intensity can be personalized.4-8 This new paradigm in patient care builds upon technology from PATHOMIQ AI, a digital pathology AI platform company. The Prolaris + AI test is the only test where AS metrics on patient results were built on studies with previously diagnosed, untreated patient cohorts.1-4 The Prolaris + AI test will continue to help doctors identify patients who are safe for single-modal treatment. AS is recommended by major clinical guidelines for men with low- and favorable intermediate-risk prostate cancer, but follow-up can vary widely by the limited ability of traditional clinical and pathology tools to predict short-term tumor behavior to help guide surveillance intensity. The Prolaris + AI Test was developed to address this gap by providing the likelihood of a higher Gleason score at next biopsy to help clinicians tailor AS protocols.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MYGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MYGN
Wall Street analysts forecast MYGN stock price to rise
5 Analyst Rating
2 Buy
2 Hold
1 Sell
Hold
Current: 6.030
Low
4.00
Averages
7.38
High
9.00
Current: 6.030
Low
4.00
Averages
7.38
High
9.00
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Myriad Genetics Releases New Data on Prolaris Test
- Clinical Data Release: Myriad Genetics has published new data on the Prolaris biopsy test, demonstrating that it provides significant prognostic information for localized prostate cancer patients beyond conventional clinical risk categories, thereby aiding physicians in making better disease management decisions.
- Large Study Scale: The analysis pooled data from 14 studies involving 8,478 patients, with individual participant data available for 7,924 patients, revealing that the Prolaris combined clinical risk score is significantly prognostic for distant metastasis and prostate cancer-specific mortality across all NCCN risk groups.
- Personalized Risk Assessment: The Prolaris biopsy test analyzes gene expression from prostate biopsy samples to generate a clinical risk score, supporting discussions between clinicians and patients regarding initial treatment options, particularly in decisions related to active surveillance and treatment escalation.
- Broad Clinical Application: The study indicates that Prolaris exhibits robust prognostic capabilities across different risk groups and management strategies, further solidifying its position as a reliable prognostic tool for localized prostate cancer patients, potentially transforming clinical practice and enhancing patient care quality.
See More
Myriad Genetics Shares Surge 8.3% Amid Optimism for Precise MRD
- Stock Surge: Myriad Genetics shares rallied 8.3% to close at $5.88 in the last trading session, with notable trading volume indicating strong investor confidence in the company's prospects.
- Product Expansion: The expanded availability of Precise MRD for breast, colorectal, and renal cancer patients has fueled investor optimism, as this next-generation assay tracks up to 1,000 variants, showcasing significant market potential.
- Earnings Outlook: Myriad is expected to report a quarterly loss of $0.03 per share, reflecting a 160% year-over-year decline, with revenues projected at $205.32 million, down 3.7% from the previous year, highlighting the challenges the company faces.
- Market Ranking: Currently holding a Zacks Rank of #2 (Buy), Myriad's earnings estimates have remained unchanged, prompting investors to monitor future earnings revisions to assess the sustainability of the recent stock price increase.
See More
Illumina Appoints New Board Member
- New Board Appointment: Illumina announced the appointment of Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026, with his extensive experience in drug discovery and clinical development expected to provide strategic advantages for the company.
- Industry Background: Skovronsky currently serves as Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, and his expertise is anticipated to aid Illumina's further development in the biotechnology sector.
- Previous Roles: Prior to this, Skovronsky was a board member at Myriad Genetics and founded Avid Radiopharmaceuticals in 2004, serving as CEO, showcasing his deep roots in the biopharmaceutical industry.
- Stock Performance: Illumina closed Tuesday's trading at $164.93, up 2.20%, and this positive market reaction may be linked to the strategic significance of the new appointment, reflecting investor confidence in the company's future growth.
See More
Myriad Genetics Expands Precise MRD Test Availability for Cancer Patients
- Market Expansion: Myriad Genetics announces the expansion of the Precise MRD test to breast, colorectal, and renal cancer patients, increasing access for over 6 million cancer patients in the U.S., significantly enhancing the company's market share in precision medicine.
- Clinical Validity Support: Results from the MONITOR-Breast study show that Precise MRD monitoring in breast cancer patients achieved a 93% baseline detection rate and demonstrated 100% specificity in predicting treatment response, further solidifying its importance in cancer management.
- Risk Stratification Capability: The study found that patients who were ctDNA positive after neoadjuvant therapy were 47 times more likely to remain ctDNA positive post-surgery, highlighting the test's potential value in personalized treatment decisions and identifying high-risk patients.
- Continuous Monitoring Advantage: Longitudinal testing revealed that 78% of patients achieved ctDNA clearance, underscoring the critical role of continuous monitoring in improving patient outcomes and aiding clinicians in adjusting treatment plans to address varying disease progressions.
See More
Myriad Genetics Appoints New Chief Technology Officer
- New CTO Appointment: Myriad Genetics appointed Raj Jampa as Chief Technology Officer effective June 1, 2026, aiming to leverage his technology leadership to scale business operations and accelerate innovation, thereby enhancing customer experience and supporting growth strategies.
- Technology Strategy Execution: Jampa will oversee the strategy and execution of Myriad's technology organization, particularly focusing on leveraging AI to drive efficiency and effectiveness, which will directly impact the company's operational model and market competitiveness.
- Rich Industry Experience: Prior to joining Myriad, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences, and Genomic Health, where he successfully led large-scale transformation initiatives, indicating his capability to modernize technology infrastructure and advance Myriad's growth strategy.
- Forward-Looking Statements: Myriad Genetics stated that Jampa's leadership will be crucial in strengthening the digital technology foundation, enhancing customer experience, and supporting the next phase of growth and value creation, reflecting the company's positive outlook on future developments.
See More
Myriad Genetics Unveils New Data on MRD Testing Across Cancer Types
- Clinical Data Showcase: Myriad Genetics will present data from six poster sessions demonstrating the utility of its Precise MRD™ test across various cancer types, particularly highlighting a 97% baseline detection rate from the MONSTAR-SCREEN-3 study, underscoring the test's significance in early cancer recurrence risk assessment.
- Ultra-Sensitive Detection Advantage: The study reveals that patients who were ctDNA-positive one month post-surgery had significantly worse disease-free survival compared to ctDNA-negative patients, emphasizing the potential value of ultra-sensitive ctDNA detection in clinical decision-making and possibly paving the way for new detection standards.
- Applicability Across Cancer Types: Myriad's research spans ovarian, gastric, head and neck cancers, and sarcoma, showcasing the clinical utility of ctDNA as a biomarker for recurrence and therapy response, further solidifying its role in precision medicine.
- Industry Expert Interaction: Myriad will offer attendees the opportunity to engage with Chief Scientific Officer Dale Muzzey during the conference, providing insights into the technical details of the Precise MRD test and its clinical evidence across multiple solid tumors, fostering knowledge sharing and collaboration within the industry.
See More
Myriad Genetics Releases New Data on Prolaris Test
- Clinical Data Release: Myriad Genetics has published new data on the Prolaris biopsy test, demonstrating that it provides significant prognostic information for localized prostate cancer patients beyond conventional clinical risk categories, thereby aiding physicians in making better disease management decisions.
- Large Study Scale: The analysis pooled data from 14 studies involving 8,478 patients, with individual participant data available for 7,924 patients, revealing that the Prolaris combined clinical risk score is significantly prognostic for distant metastasis and prostate cancer-specific mortality across all NCCN risk groups.
- Personalized Risk Assessment: The Prolaris biopsy test analyzes gene expression from prostate biopsy samples to generate a clinical risk score, supporting discussions between clinicians and patients regarding initial treatment options, particularly in decisions related to active surveillance and treatment escalation.
- Broad Clinical Application: The study indicates that Prolaris exhibits robust prognostic capabilities across different risk groups and management strategies, further solidifying its position as a reliable prognostic tool for localized prostate cancer patients, potentially transforming clinical practice and enhancing patient care quality.
See More
Myriad Genetics Shares Surge 8.3% Amid Optimism for Precise MRD
- Stock Surge: Myriad Genetics shares rallied 8.3% to close at $5.88 in the last trading session, with notable trading volume indicating strong investor confidence in the company's prospects.
- Product Expansion: The expanded availability of Precise MRD for breast, colorectal, and renal cancer patients has fueled investor optimism, as this next-generation assay tracks up to 1,000 variants, showcasing significant market potential.
- Earnings Outlook: Myriad is expected to report a quarterly loss of $0.03 per share, reflecting a 160% year-over-year decline, with revenues projected at $205.32 million, down 3.7% from the previous year, highlighting the challenges the company faces.
- Market Ranking: Currently holding a Zacks Rank of #2 (Buy), Myriad's earnings estimates have remained unchanged, prompting investors to monitor future earnings revisions to assess the sustainability of the recent stock price increase.
See More
Illumina Appoints New Board Member
- New Board Appointment: Illumina announced the appointment of Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026, with his extensive experience in drug discovery and clinical development expected to provide strategic advantages for the company.
- Industry Background: Skovronsky currently serves as Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, and his expertise is anticipated to aid Illumina's further development in the biotechnology sector.
- Previous Roles: Prior to this, Skovronsky was a board member at Myriad Genetics and founded Avid Radiopharmaceuticals in 2004, serving as CEO, showcasing his deep roots in the biopharmaceutical industry.
- Stock Performance: Illumina closed Tuesday's trading at $164.93, up 2.20%, and this positive market reaction may be linked to the strategic significance of the new appointment, reflecting investor confidence in the company's future growth.
See More
Myriad Genetics Expands Precise MRD Test Availability for Cancer Patients
- Market Expansion: Myriad Genetics announces the expansion of the Precise MRD test to breast, colorectal, and renal cancer patients, increasing access for over 6 million cancer patients in the U.S., significantly enhancing the company's market share in precision medicine.
- Clinical Validity Support: Results from the MONITOR-Breast study show that Precise MRD monitoring in breast cancer patients achieved a 93% baseline detection rate and demonstrated 100% specificity in predicting treatment response, further solidifying its importance in cancer management.
- Risk Stratification Capability: The study found that patients who were ctDNA positive after neoadjuvant therapy were 47 times more likely to remain ctDNA positive post-surgery, highlighting the test's potential value in personalized treatment decisions and identifying high-risk patients.
- Continuous Monitoring Advantage: Longitudinal testing revealed that 78% of patients achieved ctDNA clearance, underscoring the critical role of continuous monitoring in improving patient outcomes and aiding clinicians in adjusting treatment plans to address varying disease progressions.
See More
Myriad Genetics Appoints New Chief Technology Officer
- New CTO Appointment: Myriad Genetics appointed Raj Jampa as Chief Technology Officer effective June 1, 2026, aiming to leverage his technology leadership to scale business operations and accelerate innovation, thereby enhancing customer experience and supporting growth strategies.
- Technology Strategy Execution: Jampa will oversee the strategy and execution of Myriad's technology organization, particularly focusing on leveraging AI to drive efficiency and effectiveness, which will directly impact the company's operational model and market competitiveness.
- Rich Industry Experience: Prior to joining Myriad, Jampa held senior technology leadership roles at Agilent Technologies, Exact Sciences, and Genomic Health, where he successfully led large-scale transformation initiatives, indicating his capability to modernize technology infrastructure and advance Myriad's growth strategy.
- Forward-Looking Statements: Myriad Genetics stated that Jampa's leadership will be crucial in strengthening the digital technology foundation, enhancing customer experience, and supporting the next phase of growth and value creation, reflecting the company's positive outlook on future developments.
See More
Myriad Genetics Unveils New Data on MRD Testing Across Cancer Types
- Clinical Data Showcase: Myriad Genetics will present data from six poster sessions demonstrating the utility of its Precise MRD™ test across various cancer types, particularly highlighting a 97% baseline detection rate from the MONSTAR-SCREEN-3 study, underscoring the test's significance in early cancer recurrence risk assessment.
- Ultra-Sensitive Detection Advantage: The study reveals that patients who were ctDNA-positive one month post-surgery had significantly worse disease-free survival compared to ctDNA-negative patients, emphasizing the potential value of ultra-sensitive ctDNA detection in clinical decision-making and possibly paving the way for new detection standards.
- Applicability Across Cancer Types: Myriad's research spans ovarian, gastric, head and neck cancers, and sarcoma, showcasing the clinical utility of ctDNA as a biomarker for recurrence and therapy response, further solidifying its role in precision medicine.
- Industry Expert Interaction: Myriad will offer attendees the opportunity to engage with Chief Scientific Officer Dale Muzzey during the conference, providing insights into the technical details of the Precise MRD test and its clinical evidence across multiple solid tumors, fostering knowledge sharing and collaboration within the industry.
See More
